Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06990464 | A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients | recruiting | Phase 1 | 156 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07131202 | A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 130 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07161310 | Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors(MitoCancer) | recruiting | N/A | 45 | Goethe UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06235437 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 | recruiting | Phase 1 | 21 | Ascendo Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06298058 | A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. | recruiting | Phase 1 | 144 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06512116 | A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients. | recruiting | Phase 1 | 196 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07232407 | A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07321574 | A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors(ABP1011T-03) | recruiting | Phase 2 | 110 | Shanghai AB PharmaTech Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07274852 | A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05584800 | Study of ZGGS18 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 222 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05772130 | Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study | recruiting | N/A | 240 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06938880 | Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07124117 | A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | OBI Pharma, IncINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT07252414 | GenSci143 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 180 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07310134 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07232524 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 16 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06368921 | A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06882135 | HW071021 Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 76 | Wuhan Humanwell Innovative Drug Research and Development Center Limited CompanyINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07100210 | A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity | recruiting | Phase 1 | 6 | Xingchen PengOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07165067 | A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 36 | AP Biosciences Inc.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07265622 | First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT02215928 | Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors | recruiting | — | 100 | Stanford UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07197827 | A Study of YL242 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 424 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 3 | Dec 24, 2025 | clinicaltrials |
| NCT07230977 | GenSci139 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 280 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07251166 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 170 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05306132 | Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 | recruiting | Phase 1 | 150 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06459973 | A Clinical Study of YL205 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 252 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 2 | Dec 23, 2025 | clinicaltrials |
| NCT06712680 | A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes | recruiting | Phase 1 / Phase 2 | 115 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07292402 | JSKN022 in Subjects With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 225 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07229586 | A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06727812 | Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors | recruiting | Phase 1 | 206 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06825494 | Clinical Studies for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 194 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07003321 | A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07275073 | JMT106 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 200 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07290543 | Web-Based Toolkit to Improve Cancer-Related Emotional Distress and Anxiety in Rural Older Cancer Survivors | recruiting | N/A | 578 | Northwestern UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT07266285 | BTM-3566 in Advanced Solid Tumors | recruiting | Phase 1 | 30 | Bantam PharmaceuticalsINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07288957 | A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors(ABSK131-101) | recruiting | Phase 1 | 266 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06108050 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 177 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06116032 | Immune Profiling for Cancer Immunotherapy Response | recruiting | — | 1,500 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06488950 | A Study of TIL in Advanced Solid Tumors (DFGD) | recruiting | Early Phase 1 | 30 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07285395 | AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study | recruiting | Phase 1 | 12 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06383884 | Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion | recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07281326 | A Study of AK138D1 in Advanced Malignant Tumors | recruiting | Phase 1 | 200 | AkesoINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05525767 | Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer | recruiting | Phase 4 | 75 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06375187 | A Study of GC203 TIL in Advanced Malignant Solid Tumors(KUNLUN-001) | recruiting | Phase 1 | 18 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07274085 | A Phase 1 Study of HDM2017 in Advanced Solid Tumors | recruiting | Phase 1 | 96 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 8, 2026source: clinicaltrials